209 related articles for article (PubMed ID: 28114280)
1. RARRES2 functions as a tumor suppressor by promoting β-catenin phosphorylation/degradation and inhibiting p38 phosphorylation in adrenocortical carcinoma.
Liu-Chittenden Y; Jain M; Gaskins K; Wang S; Merino MJ; Kotian S; Kumar Gara S; Davis S; Zhang L; Kebebew E
Oncogene; 2017 Jun; 36(25):3541-3552. PubMed ID: 28114280
[TBL] [Abstract][Full Text] [Related]
2. Serum RARRES2 Is a Prognostic Marker in Patients With Adrenocortical Carcinoma.
Liu-Chittenden Y; Patel D; Gaskins K; Giordano TJ; Assie G; Bertherat J; Kebebew E
J Clin Endocrinol Metab; 2016 Sep; 101(9):3345-52. PubMed ID: 27336360
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
[TBL] [Abstract][Full Text] [Related]
4. Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition.
Salomon A; Keramidas M; Maisin C; Thomas M
Oncotarget; 2015 May; 6(13):11421-33. PubMed ID: 25823656
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
Gaujoux S; Pinson S; Gimenez-Roqueplo AP; Amar L; Ragazzon B; Launay P; Meatchi T; Libé R; Bertagna X; Audebourg A; Zucman-Rossi J; Tissier F; Bertherat J
Clin Cancer Res; 2010 Nov; 16(21):5133-41. PubMed ID: 20978149
[TBL] [Abstract][Full Text] [Related]
6. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
7. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
[TBL] [Abstract][Full Text] [Related]
8. Silencing of MED27 inhibits adrenal cortical carcinogenesis by targeting the Wnt/β-catenin signaling pathway and the epithelial-mesenchymal transition process.
He H; Dai J; Yang X; Wang X; Sun F; Zhu Y
Biol Chem; 2018 May; 399(6):593-602. PubMed ID: 29730647
[TBL] [Abstract][Full Text] [Related]
9. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
10. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
[TBL] [Abstract][Full Text] [Related]
11. Silencing mutated β-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R.
Gaujoux S; Hantel C; Launay P; Bonnet S; Perlemoine K; Lefèvre L; Guillaud-Bataille M; Beuschlein F; Tissier F; Bertherat J; Rizk-Rabin M; Ragazzon B
PLoS One; 2013; 8(2):e55743. PubMed ID: 23409032
[TBL] [Abstract][Full Text] [Related]
12. Wnt/β-catenin activation cooperates with loss of p53 to cause adrenocortical carcinoma in mice.
Borges KS; Pignatti E; Leng S; Kariyawasam D; Ruiz-Babot G; Ramalho FS; Taketo MM; Carlone DL; Breault DT
Oncogene; 2020 Jul; 39(30):5282-5291. PubMed ID: 32561853
[TBL] [Abstract][Full Text] [Related]
13. The effects of mitotane and 1α,25-dihydroxyvitamin D
Rubin B; Pilon C; Pezzani R; Rebellato A; Fallo F
J Endocrinol Invest; 2020 Mar; 43(3):357-367. PubMed ID: 31587178
[TBL] [Abstract][Full Text] [Related]
14. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
[TBL] [Abstract][Full Text] [Related]
15. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors.
Pereira SS; Monteiro MP; Costa MM; Ferreira J; Alves MG; Oliveira PF; Jarak I; Pignatelli D
J Cell Biochem; 2019 Jan; 120(1):894-906. PubMed ID: 30256438
[TBL] [Abstract][Full Text] [Related]
16. SIRT6 abrogation promotes adrenocortical carcinoma through activation of NF-κB signaling.
Wu X; Tian H; Xue L; Wang L
Mol Cell Biochem; 2019 Aug; 458(1-2):1-10. PubMed ID: 30989475
[TBL] [Abstract][Full Text] [Related]
17. Chemerin partly mediates tumor-inhibitory effect of all-trans retinoic acid via CMKLR1-dependent natural killer cell recruitment.
Song Y; Yin W; Dan Y; Sheng J; Zeng Y; He R
Immunology; 2019 Jul; 157(3):248-256. PubMed ID: 31063220
[TBL] [Abstract][Full Text] [Related]
18. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
19. Possible involvement of the RARRES2/CMKLR1-system in metabolic and reproductive parameters in Holstein dairy cows.
Mellouk N; Ramé C; Diot M; Briant E; Touzé JL; Guillaume D; Froment P; Dupont J
Reprod Biol Endocrinol; 2019 Feb; 17(1):25. PubMed ID: 30777067
[TBL] [Abstract][Full Text] [Related]
20. A novel FOXO1-mediated dedifferentiation blocking role for DKK3 in adrenocortical carcinogenesis.
Cheng JY; Brown TC; Murtha TD; Stenman A; Juhlin CC; Larsson C; Healy JM; Prasad ML; Knoefel WT; Krieg A; Scholl UI; Korah R; Carling T
BMC Cancer; 2017 Mar; 17(1):164. PubMed ID: 28249601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
